# OnCo record impact-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/impact-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "impact-therapeutics" ;
  schema:name "IMPACT Therapeutics"@en ;
  schema:alternateName "Impact Therapeutics, Inc."@en, "IMPACT Therapeutics (Shanghai)"@en ;
  schema:description "IMPACT is a Shanghai biotech built around DNA damage response drugs; its PARP inhibitor senaparib met its phase 3 endpoint as maintenance in ovarian cancer and is approved in China."@en ;
  schema:url <https://onco.cc/companies/impact-therapeutics/>, <https://www.impacttherapeutics.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://www.impacttherapeutics.com>, <https://clinicaltrials.gov/search?lead=Impact%20Therapeutics%2C%20Inc.>, <https://www.wikidata.org/wiki/Q140046067> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "CN" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/imp4927/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/>, <https://onco.cc/terms/clinical-trial/> ;
  onco:trials <https://onco.cc/trials/nct05269316/>, <https://onco.cc/trials/nct06907043/> .